The central focus of the Cytogenetics Shared Resource (CSR) is to provide cytogenetic and molecular cytogenetic analysis of human and animal model research samples. These samples may be in the form of cultured cells, fresh or frozen tissue, paraffin-embedded sections, or tissue microarrays (TMAs). Specific cell types include tumor cell lines, xenograft cells, hybrid cells from chimeric animal models, neural stem cells, and mouse embryonic fibroblasts, among others. The CSR provides specialized services including cell culture, routine cytogenetic analysis, chromosome breakage analysis, interphase and metaphase Fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY) analysis of human and mouse metaphases, and homebrew FISH Probe Production. This last service provides novel FISH probes that are specific to investigators needs and are usually not commercially available. These probes are then used for FISH analysis studies. The CSR is expanding this service beyond homebrew enumeration FISH probes by creating custom translocation/fusion probes, break-apart probes, and multi-color FISH probes to ultimately assist in developing strategic probes that become clinical diagnostic and prognostic markers of disease. Other services provided by the CSR to meet the needs of investigators include utilization of the CSR laboratory for slide processing and fluorescent microscope and imaging system use. Briefly, applications of CSR services include: to characterize the clonality of tumor specimens;to determine the origin of a specific tumor culture (i.e., mouse vs. human), to aid in the identification of genetic regions important for the development of specific malignancies, and to map the location of DMA sequences, genes, or transgene insertions. With the recognition that cancer is a genetic disease, many cancer researchers, including scientists in the Mayo Clinic Cancer Center (MCCC), require access to CSR services. This Shared Resource is utilized by 9 of the 12 Cancer Center Programs. Approximately 66% of CSR users are CCSG members and represent 92% of the overall utilization.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38

Showing the most recent 10 out of 340 publications